Effects of culture method on response to EGFR therapy in head and neck squamous cell carcinoma cells.
Cell Culture Techniques
Cell Line, Tumor
Cetuximab
/ pharmacology
Drug Screening Assays, Antitumor
ErbB Receptors
/ antagonists & inhibitors
Female
Head and Neck Neoplasms
/ drug therapy
Humans
Male
Morpholines
/ pharmacology
Neoplasm Proteins
/ antagonists & inhibitors
Signal Transduction
/ drug effects
Spheroids, Cellular
/ metabolism
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 08 2019
28 08 2019
Historique:
received:
16
11
2018
accepted:
06
08
2019
entrez:
30
8
2019
pubmed:
30
8
2019
medline:
21
10
2020
Statut:
epublish
Résumé
The EGFR pathway plays a critical role in head and neck squamous cell carcinoma (HNSCC). Targeted therapies against the EGFR are utilized as a treatment for HNSCCC. However, patient response is heterogeneous and molecular biomarkers are lacking to predict patient response. Therefore, functional assays where drug response is directly evaluated in tumor cells are an interesting alternative. Previous studies have shown that experimental conditions modify the drug response observed in functional assays. Thus, in this work the influence of the culture environment on response to Cetuximab (EGFR monoclonal antibody) and AZD8055 (mTOR inhibitor) was evaluated. HNSCC UM-SCC-1 and UM-SCC-47 cells were cultured in 2D monoculture and compared with: 2D co-culture with cancer-associated fibroblasts (CAF); 3D culture in collagen hydrogels; and 3D culture in tumor spheroids. The results showed UM-SCC-1 drug response significantly changed in the different culture environments; leading to an increase in drug resistance in the CAF co-culture and the 3D spheroids. Conversely, UM-SCC-47 exhibited a more constant drug response across culture conditions. In conclusion, this work highlights the importance of culture conditions that modulate response to EGFR pathway inhibition.
Identifiants
pubmed: 31462653
doi: 10.1038/s41598-019-48764-3
pii: 10.1038/s41598-019-48764-3
pmc: PMC6713778
doi:
Substances chimiques
Morpholines
0
Neoplasm Proteins
0
(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
970JJ37FPW
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Cetuximab
PQX0D8J21J
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
12480Subventions
Organisme : NIDCR NIH HHS
ID : P50 DE026787
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014520
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA211082
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA185747
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA210807
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA022443
Pays : United States
Références
Expert Opin Investig Drugs. 2010 Jun;19(6):709-22
pubmed: 20415598
Front Pharmacol. 2018 Jan 23;9:6
pubmed: 29410625
Nat Rev Cancer. 2015 Dec;15(12):747-56
pubmed: 26536825
Curr Pharm Des. 2018;24(15):1689-1694
pubmed: 29623827
Mol Cancer Ther. 2017 Jul;16(7):1257-1268
pubmed: 28446642
J Clin Oncol. 2007 Jun 1;25(16):2171-7
pubmed: 17538161
Nat Rev Drug Discov. 2015 Apr;14(4):248-60
pubmed: 25792263
J Tissue Eng. 2014 Jul 17;5:2041731414544183
pubmed: 25383169
Cancer Res. 2017 Mar 1;77(5):1188-1199
pubmed: 28031227
PLoS One. 2017 Mar 16;12(3):e0174151
pubmed: 28301591
PLoS One. 2015 Oct 07;10(10):e0139515
pubmed: 26444904
Front Oncol. 2015 Dec 17;5:282
pubmed: 26734568
Oncoimmunology. 2018 Feb 12;7(4):e1395123
pubmed: 29632716
Cell Death Dis. 2014 Feb 27;5:e1091
pubmed: 24577089
Curr Pharm Des. 2016;22(30):4717-4728
pubmed: 27145761
Oncotarget. 2016 Nov 8;7(45):74362-74379
pubmed: 27556186
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
Cancer Lett. 2014 Nov 28;354(2):365-77
pubmed: 25192874
Arch Med Sci. 2018 Jun;14(4):910-919
pubmed: 30002710
Mol Diagn Ther. 2012 Aug 1;16(4):209-22
pubmed: 22873739
J Cell Sci. 2017 Jan 1;130(1):203-218
pubmed: 27663511
Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2852-E2861
pubmed: 28320945
Cancer Res. 2018 Aug 1;78(15):4331-4343
pubmed: 29792310
Semin Radiat Oncol. 2009 Jan;19(1):63-8
pubmed: 19028347
Oncoimmunology. 2018 Dec 12;8(3):1553477
pubmed: 30723584
Mol Cancer Res. 2012 Sep;10(9):1158-68
pubmed: 22809838
Oral Maxillofac Surg Clin North Am. 2014 May;26(2):123-41
pubmed: 24794262
Anticancer Res. 2018 Mar;38(3):1445-1454
pubmed: 29491070
Oncotarget. 2015 Apr 10;6(10):7454-69
pubmed: 25762634